Pfizer’s Sigvotatug Vedotin Fails Primary Endpoint in NSCLC Trial
Event summary
- Pfizer’s Phase 3 SigVie-002 trial for sigvotatug vedotin in metastatic non-squamous NSCLC failed to meet the primary endpoint of overall survival (OS) compared to docetaxel.
- The study enrolled 703 patients, with two-thirds receiving only one prior line of therapy.
- In second-line patients, sigvotatug vedotin showed a stronger trend for OS and progression-free survival (PFS) over docetaxel.
- Pfizer is continuing to evaluate sigvotatug vedotin in combination with pembrolizumab in first-line NSCLC.
The big picture
Pfizer’s setback in the SigVie-002 trial highlights the challenges of developing novel therapies for heavily pre-treated NSCLC patients. The company is pivoting to combination strategies, leveraging its ADC portfolio and post-Seagen acquisition capabilities to target earlier treatment lines where immune competence is better preserved. This aligns with broader industry trends toward personalized oncology approaches and multi-modal therapeutic combinations.
What we're watching
- Combination Strategy
- Whether Pfizer’s ongoing Phase 3 trial of sigvotatug vedotin with pembrolizumab in first-line NSCLC can demonstrate superior efficacy.
- Pipeline Depth
- The pace at which Pfizer advances other ADC candidates, including fetrastobart vedotin and novel bispecific antibodies.
- Regulatory Pathway
- How the exploratory data from SigVie-002 influences future regulatory discussions for sigvotatug vedotin.
Related topics